Varun Goel
Rajiv Gandhi Cancer Institute and Research Centre, IndiaPresentation Title:
Study of efficacy and toxicity of capecitabine maintenance after response to docetaxel, cisplatin, and 5-Fluracil-based chemotherapy in advanced carcinoma stomach
Abstract
Background: Advanced gastric cancer is associated with poor survival despite chemotherapy. Maintenance chemotherapy has been successfully tried in lung cancer and colorectal cancers however there is scarce literature on maintenance therapy in advanced gastric cancer. We report a prospective non-randomized single-arm trial of capecitabine maintenance after response to docetaxel, cisplatin, and 5-Flurouracil-based chemotherapy.
Methods: 50 patients with advanced gastric cancer, who had achieved response or had stable disease after 6 cycles of Docetaxel, Cisplatin, and 5-Flurouracil (D 75 mg/m2, C 75 mg/m2, FU 750 mg/m2/d d1-d5, q3 weeks) chemotherapy were prospectively selected to receive maintenance chemotherapy with capecitabine (1000mg/ m2 bid d1-d14 q21 days) until progression.
Results: During the median follow-up period of 18 months all patients had progressed, however, there was no treatment-related death, the median time to tumor progression was 10.3 months, with grade 3 and 4 toxicities in 10-15% of patients, and treatment delays in 75% of patients.
Conclusions: Our study has shown that maintenance chemotherapy with capecitabine post-first-line docetaxel, cisplatin, and 5-FU-based chemotherapy is effective and delays tumor progression. However, toxicity was a concern in our study which led to treatment-related delays but without any treatment-related death. Most patients continued therapy till progression.
Biography
Dr. Varun Goel is a Senior Consultant and Principal Coordinator of Day Care Services in the Department of Medical Oncology at Rajiv Gandhi Cancer Institute and Research Centre, New Delhi. He holds an MD in Medicine and DNB in Medical Oncology, with additional qualifications including MRCP (UK) in Medical Oncology and ECMO certification. With over 15 years of clinical experience, Dr. Goel has been at the forefront of comprehensive cancer care, focusing on precision oncology, immunotherapy, and breast cancer research. He is actively involved in clinical practice, academic training, and ongoing research, serving as a thesis co-guide for DNB students and contributing extensively to national and international oncology conferences. Dr. Goel has authored over 50 peer-reviewed publications and multiple book chapters on breast, hepatobiliary, and gynecologic malignancies.He has been recognized with several awards, including the Health Icon of the Year (2016) and the Medical Excellence Award (2025). His participation in global preceptorships and research collaborations reflects his commitment to advancing cancer care in India and beyond. His current research interests include immunotherapy integration in solid tumors and real-world evidence generation from Indian cancer populations.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Drop us an email for Program enquiry
breastcancer@scientexconferences.com
General Queries
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
breastcancer@scientexevents.org
Our Social Presence
Call us at
Whatsapp : (+1) 914 520 5013